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1. Introduction 
Complex 111, ubiquinol-cytochrome c reductase 
(EC 1.10.2.2), is a membranous multiprotein com- 
plex of the mitochondrial respiratory chain [ 1,2]. 
Although many inhibitors of complex Ill are now 
known, 2 are most frequently used as a tool to eluci- 
date the electron transfer mechanism in this region of 
the respiratory chain, namely antimycin [3] and the 
2-n-alkyl derivatives of 4-hydroxyquinoline N-oxide 
[4,51. 
It is not yet well understood whether these 2 inhib- 
itors bind to the same site [4,6-81 or to different sites 
[9-l 11, and whether there are other binding sites for 
each [3,9,12,13]. 
We decided to tackle this problem by studying the 
binding of 3-3H-2-n-Nonyl-4-hydroxyquinoline 
N-oxide ( [3H]NoHOQnO) to the already well-charac- 
terized complex 111, purified by the fast Triton- 
hydroxyapatite procedure [ 14- 171. Since the inhibi- 
tors are highly lipophilic, thus having a great affinity 
for the membranous lipidic phase, it offers the advan- 
tage of working on a membrane free model. 
This paper reports on the purification and charac- 
terization of the [3H]NtiHOQnO-loaded complex Ill. 
This binding is specifically recognized by NoHOQnO, 
antimycin and by 5-n-undecyl-6-hydroxy-4,7-dioxo- 
benzothiazole (UHDBT). The results obtained by 
these competition studies are discussed below. 
2. Materials and methods 
Beef heart mitochondria were prepared according 
to [ 181. [3H]NoHOQn0 was synthesized by Dr H. 
Gtinther as in [5]. 
NoHOQnO (Research Plus Laboratories) and 
UHDBT were generous gifts from Professor B. L. 
Trumpower. [3H]Antimycin was kindly donated by 
Professor G. von Jagow. Antimycin was obtained 
from Boehringer, hydroxyapatite (HTP) from Bio-Rad 
Labs and Triton X-100 from Sigma. 
NoHOQnO, antimycin, cytochrome b and protein 
concentrations were determined as in [5]. Protein 
content was also routinely determined by the Bio-Rad 
protein assay. A modified Lowry [ 191 procedure was 
used for the purified complex Ill fractions. 
Equilibrium dialysis experiments were carried out 
with the apparatus of Diachema (Zurich) for 6-30 h 
at 4OC. The purified [‘H]NoHOQnO-complex Ill 
was added to a 200 ~1 half-cell, the antagonists to the 
opposite half-cell. Cellulose dialysis tubing, obtained 
from Serva, were boiled in 0.2 SnClz g/l and washed 
several times with water. 
Polyacrylamide gel electrophoresis in sodium 
dodecyl sulfate (SDS-PAGE) was done essentially 
according to [20], as described in [21]. 
3. Results 
[3H]NoHOQn0 is a highly hydrophobic com- 
pound. For the solubilization and the purification of 
its binding site in an intact state, it is necessary to 
maintain detergent concentration as low as possible 
[22]. This was obtained by adding sucrose to the 
extraction medium and by lowering the Triton con- 
centration during the chromatographic and dialysis 
steps. 
The purification procedure is summarized in fig.1. 
After the solubilization of the particles, -70% of the 
protein fraction, 80% of cytochrome b and 85% of 
radioactivity were recovered in the Triton extract. 
Complex Ill was bound in a batch procedure to 
222 
Published by Elsevier Biomedical Press 
00145793/82/0000-0000/$02.75 0 1982 Federation of European Biomedical Societies 
Volume 137, number 2 FEBS LETTERS January 1982 
BFFF WART MITOCHONDRIA 
I 1. ADDITION OF 3h -NoHOQnO 2. CENTRIFUGATION, 60' AT 160,000 x g 
i3HI-NoHObO - BHM. 
I 
1. NEGATIVE EXTRACTION WITH 1,65% TRI_ 
TRON, 200 mM NaCl. 20 mM MOPS, pH 
7.2, AT 15 MG PROTEIN/ML, 15’ AT 4.C 
2. CENTRIFUGATION, 60' AT 160.000 X G 
i3~I- Nc&MNO - SUBMLES 
I 
1. EXTRACTION WITH 3% TRITON X-'100, ll%, 
SUCROSE: 220 mM NaCl. 20 mM MOPS, pH 
7.2, AT 10 MG PROTEIN, 15' AT 4-C. 
2. CENTRIFUGATION.20' AT 160.000 X G. 
1. ADDITIDN OF HYDRDXYAPATITE, 1.1-1.5 ML 
HTP/ML EXTRACT 
2. PACKING INTO A COLUMN 
3. ELUTION WITH 0.4 M PHOSPHATE 
[ 3H]_NaHOQNO_ 
coMp,Fx ,rl 
1. DIALYSIS vs 0.05% TRITON X-100, 10 mM 
MOPS, 30 mM NaCl ( 3 HOURS) 
2. CENTRIFUGATION, 20' AT 160.000 X G 
TO EQUILIBRIUM DIALYSIS 
Fig.1. Summary of the purification of [SH]NoHOQnO com- 
plex HI. Preparation time: -2 h, starting from the extraction 
of the [ sH JNoHOQnO-loaded submitochondrial particles. 
Enrichment, lo-11-fold. 
El. II 
4 
El. 111 
I 
20 
Fraction number 
F&2. Eluate profile of a hydroxyapatite column: eluent I, equilibrating medium as in text; eluent II, 0.05% Triton X-100, 10 mM 
MOPS, 150 mM phosphate (pH 7.2); eluent III, 0.05% Triton X-100,10 mM MOPS, 400 mM phosphate (pH 7.2); 3.75 ml/fraction, 
60 ml/h. Protem content was determined by the Bio-Rad assay. Fraction 27 contains 3.7 PM cytochrome b, 0.53 mg protein/ml 
(Lowry), 5420 cpm/ml. 
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hydroxyapatite equilibrated with 0.05% Triton X-100, 
20 mM morpholirropropane sulfonate (MOPS), 30 mM 
NaCl, at pH 7.2, then packed into a column. Free or 
so-called unspecific bound [3H]NoHOQn0 and 
excess Triton X-100 pass through the column (fig.2) 
whereas complex III precipitates in the column. 
Phosphate application in concentrations normally 
used for the elution of complex III, 150-200 mM 
[ 14- 161, does not permit recovery. 
The [3H] NoHOQnO-complex III is eluted only 
by means of 400 mM phosphate, to a purity of 
6.6-7.0 pmol cytochrome b/g protein, in fractions 27 
and 28. 
In spite of the different elution molarity, eluted 
complex HI is intact. It still contains cytochromes b 
5f 
/ 
I I I 1 
550 600 X Ctml 
Fig.3. Difference absorbance spectrum of the complex III 
collected in fraction 27 (fig.2). Reduced by dithionite and 
oxidized by ferricyanide. 
I A = 0.05 
59 
81 
and cl (fig.3) and the other polypeptides, the iron- 
sulfur protein included (fig.4). 
Therefore, as determined by gel filtration, the 
[3H]NoHOQnO-complex III has the same app. Mr as 
[3H]antimycin-complex III, prepared in a similar 
way but eluted by 150 mM phosphate in the presence 
of higher Triton concentrations in the eluent (not 
shown). 
Purified [3H] NoHOQnO binding was further char- 
acterized by equilibrium dialysis studies (section 3.1). 
3.1. Interaction of other complex ZZZ ligands with 
[3H]NoHOQn0 binding 
The [3H]NoHOQn0 specific binding has been 
defined in submitochondrial particles as a saturable, 
antimycin-sensitive binding [3,4,23]. 
To test if the isolated [3H]NoHOQn0 binding is 
specific the [3H]NoHOQnO-complex III was sub- 
mitted to equilibrium dialysis in the presence of 
either NoHOQnO, antimycin or UHDBT. 
26 
Fig.4. SDS-PAGE: polypeptide pattern of purified [sH]- 
NoHOQnO-complex III. 
224 
Volume 137, number 2 FEBS LETTERS January 1982 
A ANTIMYCIN 
0.25 
added ANTAGONIST CmM 1 
0.50 
Fig.5. Demonstration of ligand interaction with the [3H]NoHOQnO-complex III as determined by equilibrium dialysis for 
15-30 h at 4°C. 100% corresponds to 51% binding in the control. Dialysis medium: 0.05% Triton X-100, 10 mM MOPS, 30 mM 
NaCl (pH 7.2). Free [‘HjNoHOQnO reached the equilibrium in 3-4 h. In a typical experiment he protein sample contained 
0.74 nmol cytochrome b, 0.11 mg protein, 1084 cpm, in 200 ~1. Ligands were added in ethanolic solutions to the opposite half- 
cell. Ethanol final concentration did not exceed 4.5%. 
Fig.5 shows the displacement of bound [3H]- 
NoHOQnO as the dependence of [3H]NoHOQn0 
binding on the concentration of the added ligands. 
Rather than the expected difference in curves, a single 
curve can be drawn which is roughly valid for the 
action of all 3 ligands. However, the removal of bound 
[3H]NoHOQn0 should be ascribed to a specific inter- 
action of the added ligands with the [3H]NoHOQn0 
binding site, since the unrelated lipophilic compound 
rotenone, added to 46 PM, does not remove any 
bound [ 3H] NoHOQnO.(not shown). 
4. Discussion 
The [‘H]NoHOQnO specific binding has been iso- 
lated in its intact and functional state. No other [3H]- 
NoHOQnO binding could be detected. 
The similar effectiveness of the 3 ligands, NoHOQnO, 
antimycin, and UHDBT, in removing bound [3H]- 
NoHOQnO has to be explained since antimycin 
(Kd,s = 10-“-10-‘3 M) [3] was expected to display 
[‘H]NoHOQnO much better than NoHOQnO (& = 
5 X lO+ M) [5] and UHDBT should not have inter- 
acted with the [3H]NoHOQn0 binding site. 
These results can be best explained by the assump- 
tion of different binding sites for NoHOQnO and 
antimycin. If so, the question arises as to the location 
of the NoHOQnO binding site. 
[3H]NoHOQn0 bound to the purified complex III 
is displaced from 2 different types of inhibitors such 
as antimycin and UHDBT: antimycin binds to cyto- 
chrome b [24] near the heme center bsb2 [6,25,26]; 
whereas UHDBT apparently binds to the iron-sulfur 
protein [27,28]. 
However, a structural interaction between the 
iron-sulfur protein and cytochrome b has been pro- 
posed in [29] and therefore it is known that the 
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Rieske iron-sulfur protein can be split from com- 
plex III in the presence of antimycin [14,301. 
The displacement of bound [3H]NoHOQn0 by 
antimycin could be explained by negative allosteric 
interaction between 2 different binding sites [lo], 
whereas the [3H]NoHOQn0 displacement by UHDBT 
should be ascribed to either proximity or identity of 
the [‘H]NoHOQnO and UHDBT binding sites. 
We can assume that the NoHOQnO binding site is 
located either on a cytochrome b region near the 
association site of the Rieske iron-sulfur protein, or 
on the Rieske protein itself. In other words the bind- 
ing site should be near the reacting sites of QH:, the 
non-diffusible ubisemiquinone of complex III [28]. 
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